Traditional angiography has been done from the leg through the large femoral artery.
This is uncomfortable and awkward for the patient, with higher risks associated with bleeding from the artery and longer recovery times and periods lying flat post procedure.
Moving to a transradial approach offers the opportunity of faster, safer patient-centred care.
The transradial market is expanding and is set to reach $24.9 Billion by 2030. Catheters are the fastest growth area within this sector.
The radial artery however is small, tortuous and prone to spasm.
Navigating it can be technically challenging, limiting the size and range of interventions.
A product that could allow enhanced radial access would be a boon to the medical community, saving time, cost and patient discomfort.
The innovative design of the RadiCath provides a much greater chance of transradial access to the heart than traditional catheters.
Safe and effective, RadiCath is versatile and simple to use with a wide range of catheter shapes and sizes. Now UK patent pending.
Dr Robin van Lingen
is an Interventional Cardiologist with a wealth of Cardiology experience across a wide range of sub-specialities (www.cardiologycornwall.com). His innovation and entrepreneurial interests include being Founder and Medical director of the digital health company Metronome and designing an innovative surgical field for Interventional procedures.
T: +44 7767215245 E: info@radicath.com
radicath.com 